30
Participants
Start Date
July 15, 2020
Primary Completion Date
December 22, 2022
Study Completion Date
January 31, 2023
AK104
All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
The Blavatnik Family - Chelsea Medical Center at Mount Sinai, New York
Monter Cancer Center, Lake Success
Maryland Oncology Hematology (Plum Orchard), Silver Spring
Virginia Commonwealth University, Richmond
Virginia Oncology Associates, Norfolk
Augusta University Medical Center, Augusta
Sylvester Comprehensive Cancer Center, Miami
BRCR Medical Center, Plantation
Tennessee Oncology - Centennial Clinic, Nashville
Chattanooga's Program In Women's Oncology, Chattanooga
Oncology Hematology Care Inc, Cincinnati
Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
University of Texas Southwestern, Dallas
Texas Oncology-Fort Worth Cancer Center, Fort Worth
Lyndon B. Johnson Hospital (MD Anderson), Houston
Texas Oncology (Woodlands), The Woodlands
Womens Cancer Research Foundation, Newport Beach
Pacific Gynecology Specialists, P. C., Seattle
Illinois Cancer Specialists, Arlington Heights
Monash Health, Clayton
Sir Charles Gairdner Hospital, Nedlands
Ashford Cancer Centre Research, Adelaide
Blacktown Hospital, Blacktown
ICON Cancer Centre, Brisbane
Auckland City Hospital, Grafton
Lead Sponsor
Akesobio Australia Pty Ltd
INDUSTRY
Akeso
INDUSTRY